Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. The Company seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Type
Public
HQ
Newtown, US
Founded
1998
Size (employees)
23 (est)-36%
Onconova Therapeutics was founded in 1998 and is headquartered in Newtown, US
Report incorrect company information

Key People/Management at Onconova Therapeutics

Ramesh Kumar

Ramesh Kumar

President and CEO

Onconova Therapeutics Office Locations

Onconova Therapeutics has an office in Newtown
Newtown, US (HQ)
375 Pheasant Run
Show all (1)
Report incorrect company information

Onconova Therapeutics Financials and Metrics

Onconova Therapeutics Financials

Onconova Therapeutics's revenue was reported to be $5.55 m in FY, 2016
USD

Revenue (Q3, 2017)

110 k

Net income (Q3, 2017)

(7 m)

EBIT (Q3, 2017)

(6.8 m)

Market capitalization (5-Feb-2018)

10.5 m

Cash (2-Feb-2018)

7.6 m
Onconova Therapeutics's current market capitalization is $10.5 m.
Annual
USDFY, 2016

Revenue

5.5 m

General and administrative expense

9.2 m

R&D expense

20.1 m

Operating expense total

29.2 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

125 k114 k114 k123 k1.6 m1.5 m2.2 m1.7 m210 k110 k

General and administrative expense

4 m3.1 m3 m2.6 m2.2 m3.2 m2.1 m2 m2.1 m

R&D expense

12.9 m11.9 m9.5 m6.5 m5.3 m5.8 m5.6 m4 m4.9 m

Operating expense total

16.9 m15 m12.5 m9.1 m7.5 m9 m7.6 m6 m7 m6.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

60 m43.6 m19.8 m21.4 m

Accounts Receivable

141.8 m

Inventories

4.4 m3.2 m1.8 m

Current Assets

104.4 m46.9 m23.2 m23.1 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Cash

55.5 m42.3 m33.7 m25.4 m22.2 m16.8 m12.8 m25.8 m15.4 m7.6 m

Inventories

1 m

Current Assets

73.8 m61.6 m36.4 m27.4 m25.7 m19.4 m16 m27.9 m16.4 m8.7 m

PP&E

609 k512 k348 k300 k273 k224 k200 k176 k129 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.6 m)(63.8 m)(24 m)(19.7 m)

Depreciation and Amortization

446 k434 k150 k96 k

Inventories

(2.7 m)1.2 m1.2 m

Accounts Payable

(1.8 m)317 k(606 k)1.9 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(16.8 m)(14.9 m)(12.4 m)(9 m)(5.9 m)(7.2 m)(5.4 m)(1.6 m)(8.3 m)(7 m)

Depreciation and Amortization

24 k

Inventories

1 m

Accounts Payable

5 m5.4 m3.9 m4.2 m3.2 m(125 k)2.8 m4.1 m5.4 m5.4 m
Show all financial metrics
Report incorrect company information